Ezetimibe vs Testosterone
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Ezetimibe and Testosterone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Ezetimibe Testosterone
Weight 409.43 Da 288.42 Da (base)
Half-life ~22 hours ~8 days (cypionate)
Type Azetidinone (C24H21F2NO3) Steroid hormone (C19H28O2)
Key Benefits
Ezetimibe
01 Reduces LDL cholesterol by 15-20% as monotherapy
02 Complementary mechanism to statins allows additive LDL reduction of 25% when combined
03 Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
04 Simple once-daily dosing with no titration required
05 No significant impact on CoQ10 levels (unlike statins)
06 Well tolerated with a side effect profile comparable to placebo in clinical trials
07 Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
08 Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
Ezetimibe
10 mg/day / Once daily
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
Ezetimibe
Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
Fatigue and headache (uncommon, typically transient)
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
Known hypersensitivity to ezetimibe or any component of the formulation
Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
Pregnancy and breastfeeding (when used in combination with a statin)
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
Ezetimibe Testosterone
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2023 June 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.